Huntington's Disease: Chromosome 4 CAG Repeat Expansion
Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene (huntingtin gene) located on the short arm of chromosome 4 (4p16.3).
Genetic Thresholds
- Normal: ≤35 CAG repeats — no disease risk.
- Intermediate (reduced penetrance): 36–39 repeats — may not develop symptoms but can expand in offspring.
- Pathogenic (full penetrance): ≥40 repeats — virtually certain to develop HD if lifespan permits.
Inheritance Pattern
HD follows autosomal dominant inheritance. Each child of an affected parent has a 50% chance of inheriting the expanded allele. The repeat size tends to expand further during paternal transmission (anticipation), leading to earlier onset in successive generations.
Pathophysiology
The expanded CAG tract translates into an elongated polyglutamine (polyQ) stretch in the huntingtin protein. This mutant protein misfolds, forms aggregates, and exerts toxic effects—particularly on striatal and cortical neurons—through disrupted transcription, mitochondrial dysfunction, impaired axonal transport, and excitotoxicity.
Clinical Features
- Motor: Chorea (involuntary, dance-like movements), dystonia, rigidity, gait impairment, dysarthria, dysphagia.
- Cognitive: Executive dysfunction, slowed processing, memory impairment, eventual dementia.
- Psychiatric: Depression, anxiety, irritability, apathy, psychosis, suicide risk (elevated).
Onset typically occurs in mid-adulthood (30s–50s), but juvenile HD (<20 years) and late-onset (>60) exist. Earlier onset correlates with larger repeat expansions.
Diagnosis and Testing
- Genetic testing (PCR/southern blot for CAG repeat size) confirms the diagnosis in symptomatic individuals.
- Predictive testing is available for at-risk adults (usually ≥18) with extensive pre- and post-test genetic counseling, neurological exam, and psychiatric assessment. It is a deeply personal decision with profound implications.
While no disease-modifying therapy exists yet, multidisciplinary care (neurology, psychiatry, genetics, social work) optimizes quality of life. Clinical trials targeting HTT lowering (antisense oligonucleotides, gene silencing) are underway.
Genetic Disorders - Related Articles
- Diagnosing Mononucleosis: Clinical Evaluation, Monospot Test, CBC, and EBV-Specific Antibody Testing
- Borderline Personality Disorder Trajectory: Can Symptoms Worsen with Age?
- Restriction Mapping: Principles, Applications & Modern Alternatives
- Tay-Sachs Inheritance: Autosomal Recessive Genetics and Family Risk
- Inherited Mutations: Germline vs. Somatic vs. Chromosomal — Transmission and Consequences
- Sex-Linked Traits: X-Linked Inheritance Patterns and Common Examples
- Marfan Syndrome and the FBN1 Gene: Molecular Mechanisms and Clinical Implications
